Kidswell Bio EBITDA per Share

What does Kidswell Bio do? Kidswell Bio Corp develops biopharmaceutical products, focusing on biosimilar filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The company also researches anti-RAMP2 antibodies for cancer and eye diseases, new antibodies, and regenerative medicine using intracardiac stem cells for pediatric heart conditions and dental pulp stem cells for cleft lip, palate, and intestinal ganglion cell deficiency. Revenue comes from the biosimilar business, new biopharmaceutical business, and new biotechnology business, targeting healthcare providers and medical institutions seeking cost-effective treatments. The biosimilar products include filgrastim and pegfilgrastim for cancer, darbepoetin alfa for renal diseases, and ranibizumab for eye diseases. The new biopharmaceutical business develops anti-RAMP2 antibodies and new antibodies, while the new biotechnology business focuses on regenerative medicine with stem cell applications. These products are sold to hospitals, clinics, and research institutions requiring advanced biopharmaceutical solutions. Kidswell Bio Corp's revenue streams are derived from the sale of biosimilar products, anti-RAMP2 antibodies, and regenerative medicine solutions. The company targets healthcare providers in oncology, nephrology, ophthalmology, and regenerative medicine sectors. Sales are driven by the demand for affordable alternatives to branded biologics, with a focus on pediatric and chronic disease treatments. Kidswell Bio is one of the most popular companies on Eulerpool.